In the Children’s Cancer Group (CCG) study, FLT3-ITD was present in 77 of the 360 tested patients (12%) [16], and in the study performed by the AML-BFM Study Group, this mutation was found in 52 out of the 353 analyzed patients (15%) [17]. This evidence concerns the gene FLT3 and cancer.